For localized information and support, would you like to switch to your country-specific website for {0}?
AVENIO ctDNA Expanded Kit V2
RUO
For Research Use Only. Not for use in diagnostic procedures.
Pan-cancer assay optimized for lung and colorectal cancer research
The AVENIO ctDNA Expanded Kit V2 is a next-generation sequencing (NGS) liquid biopsy research use only assay with a 77 gene panel containing genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. It is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC) research.
AVENIO ctDNA Expanded Kit V2 analytical performance3
View full tableAVENIO ctDNA Expanded Kit V2 analytical performance3
Mutation class |
SNVs |
Indels |
Fusions |
CNVs** |
|||
| Mutant allele frequency/copy number | 0.5%* | 1.0%* | 1.0% | Sample dependent
|
|||
|---|---|---|---|---|---|---|---|
| Sensitivity and PPV | Sensitivity | PPV | Sensitivity | PPV | Sensitivity | PPV | |
| >99% | >95% | >99% | >99% | >99% | >99% | ||
**The kit reports ERBB2, EGFR, and MET CNVs. Performance is dependent on various factors, including sample type, input DNA amount, percent tumor content, and the individual tumor's genomic copy number. Our technical study detected CNVs at dPCR-verified copy numbers, using a commercially available reference sample (50ng). CNV specificity was high (PPV >99%). ERBB2 detected at 2.2 copies, MET detected at 2.6 copies.
Performance samples: Seraseq ctDNA Complete Mutation Mixes (SeraCare), healthy donor cfDNA.
Sensitivity and Positive Predictive Value (PPV) metrics based on observed product performance. Sensitivity and PPV performance reported per variant. Sensitivity was determined using commercially available reference samples containing verified mutations at the stated allele frequencies. SNV performance data based on hotspot calls. The AVENIO ctDNA Analysis Kit V2 can achieve >99.99% per base specificity across each of the panels. Stated performance requires at least 40 million reads per sample for all AVENIO ctDNA Panels V2. Sequencing performed on an Illumina NextSeq 500/550/550Dx (Research Use Only mode) instrument.
AVENIO ctDNA Expanded Kit V2 specifications
View full tableAVENIO ctDNA Expanded Kit V2 specifications
Product specifications |
Value |
Panel size |
192 kb |
Sample size |
4 ml of plasma |
cfDNA input |
10-50 ng |
Reactions per kit |
16 |
Turn-around time |
5 days from extraction to results |
Use left and right arrow keys to scroll between the tabs
Overview
Technical documents
Access important product documentation including relevant certificates and other resources.
After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
Key product features
NCCN guideline genes: The assay includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1
All mutation classes: All four mutation classes (SNVs, indels, fusions, and CNVs) are included in one assay.
Comprehensive package: The assay is inclusive of reagents, bioinformatics, and software.
AVENIO ctDNA Kit comparison overview
AVENIO ctDNA Targeted Kit V2
|
AVENIO ctDNA Surveillance Kit V2
|
AVENIO ctDNA Expanded Kit V2
|
|
| Disease targets | |||
|
Lung, Colorectal, Breast, Gastric, Glioma, Melanoma, Ovarian, Thyroid, Pancreatic
|
Lung, Colorectal; Secondary: Breast, Gastric, Prostate, Glioma, Melanoma, Ovarian, Thyroid, Pancreatic
|
Lung, Colorectal, Breast, Gastric, Prostate, Glioma, Melanoma, Ovarian, Thyroid, Pancreatic
|
|
| Applications | |||
|
Tumor Profiling 17 genes (18kb); Non-invasive tumor profiling; Non-invasive detection of resistance biomarkers.
|
Tumor Burden Monitoring 197 genes (198 kb), includes 17 genes from targeted panel; Non-invasive tumor profiling; Non-invasive detection of resistance biomarkers; Non-invasive serial tumor burden monitoring; Non-invasive detection of minimal residual disease (MRD).
|
Expanded Tumor Profiling 77 genes (192 kb), includes 17 genes from targeted panel; Non-invasive tumor profiling; Non-invasive detection of resistance biomarkers Investigation of emerging cancer biomarkers.
|
|
| Sample input | |||
|
ctDNA from 4mL plasma, 10-50ng cfDNA input
|
ctDNA from 4mL plasma, 10-50ng cfDNA input
|
ctDNA from 4mL plasma, 10-50ng cfDNA input
|
|
| Mutation classes | |||
|
SNVs, CNVs, Fusions, Indels; from just 10-50 ng of cfDNA
|
SNVs, CNVs, Fusions, Indels
|
SNVs, CNVs, Fusions, Indels; from just 10-50 ng of cfDNA
|
|
| Performance | |||
|
Delivers exceptional analytical performance supported by integrated digital error suppression (iDES) strategies, combining molecular barcodes with in silico error suppression techniques.†,††
|
Delivers exceptional analytical performance supported by integrated digital error suppression (iDES) strategies, combining molecular barcodes with in silico error suppression techniques.†,††
|
Delivers exceptional analytical performance supported by integrated digital error suppression (iDES) strategies, combining molecular barcodes with in silico error suppression techniques.†,††
|
|
| Throughput | |||
|
Up to 16 reportable results per kit
|
Up to 16 reportable results per kit
|
Up to 16 reportable results per kit
|
|
| Time to result | |||
|
Streamlined workflow <5 days from tissue DNA extraction to final report
|
Streamlined workflow <5 days from tissue DNA extraction to final report
|
Streamlined workflow <5 days from tissue DNA extraction to final report
|
|
| Workflow efficiency | |||
|
Reduce operational complexity by obtaining reagents for cfDNA isolation from plasma, library prep, and target enrichment from a single trusted vendor.
|
Reduce operational complexity by obtaining reagents for cfDNA isolation from plasma, library prep, and target enrichment from a single trusted vendor.
|
Reduce operational complexity by obtaining reagents for cfDNA isolation from plasma, library prep, and target enrichment from a single trusted vendor.
|
|
| Algorithm | |||
|
Analyze a variety of solid tumor indications for research using a single optimized DNA workflow for up to 16 samples at a time.
|
Uses an intelligent algorithm that applies population-scale data from multiple cancer databases to design a panel with broad coverage.
|
Analyze a variety of solid tumor indications for research using a single optimized DNA workflow for up to 16 samples at a time.
|
|
| Cost efficiency | |||
|
Receive a complete solution with the required reagents, a robust bioinformatics pipeline, and software for analysis and reporting to keep your lab at the forefront of cancer research.
|
Maximizes the number of mutations detected per tumor while minimizing the panel size, enabling researchers to use the combined power of multiple mutations to increase the detection of ctDNA several fold while minimizing sequencing costs.†,††
|
Receive a complete solution with the required reagents, a robust bioinformatics pipeline, and software for analysis and reporting to keep your lab at the forefront of cancer research.
|
|
† National Comprehensive Cancer Network. [Internet; accessed August 2, 2023]. Available from: https://www.nccn.org/
†† Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.
Related products
AVENIO assays are for Research Use Only. Not for use in diagnostic procedures.
References
- National Comprehensive Cancer Network [Internet; cited 2025 Nov 20]. Available from: https://www.nccn.org/
- Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Med. 2014;20(5):548–554 doi:10.1038/nm.3519. Available from: https://www.nature.com/articles/nm.3519
- F. Hoffmann-La Roche Ltd. Data on file.